$NVAX H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax on Monday, setting a price target of $294, which is approximately 45.58% above the present share price of $201.95

$NVAX Европейское агентство по лекарственным средствам рекомендовало выдать условное разрешение на продажу вакцины Novavax против COVID-19 (также известной как NVX-CoV2373) для профилактики COVID-19 у людей в возрасте от 18 лет и старше https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu?s=09

$NVAX has $15 billion+ sales in 2022 at $16 billion market cap. BioNTECH market cap is $70 billion. $NVAX needs to be at $920 to get a market cap of $70 billion. #ema approval is coming next week #uk approval is coming in December #india approval is coming in January #fda approval is coming in January #japan approval is coming in January #korea approval is coming in January #nvax flu vaccine is coming in July of 2022

$NVAX - World Health Organization to consider Emergency Use Authorization (EUA) of SII's Covovax today. - Novavax files for EUA in Japan just now.

$MRNA Researchers at the University of Oxford, the same university that helped develop drug company AstraZeneca’s vaccine, found that the rare blood clotting known as cerebral venous thrombosis occurred in four in a million people receiving the vaccines from drug company Pfizer and biotech Moderna.

>> $MRNA <<

$MRNA https://www.canada.ca/en/public-health/news/2020/12/government-of-canada-officials-to-hold-technical-briefings-on-covid-19-vaccines-in-canada.html